CEO Executive AssistantBiosimilar company CEO time management across development and market access is one of the most compressed and execution-dependent challenges in pharmaceutical leadership. Biosimilar development combines the scientific rigor of demonstrating analytical and clinical similarity to a reference biologic with the competitive urgency of a race against both the reference product’s legal defense strategies and other biosimilar developers targeting the same molecule. CEOs of biosimilar companies operate in a business where the development timeline, the regulatory strategy, and the launch timing decision are all inseparably connected, and where a mistake in any one dimension compounds the others.
The Biosimilar Development and Regulatory Timeline
Biosimilar development in the United States operates under the Biologics Price Competition and Innovation Act pathway administered through FDA’s Center for Drug Evaluation and Research. The 351(k) approval pathway requires comprehensive analytical similarity characterization, functional assays, animal studies where appropriate, and a clinical program designed to demonstrate there are no clinically meaningful differences between the biosimilar and the reference product.
The analytical similarity package is the foundation of a biosimilar submission, and it is where the most scientifically complex work occurs. CEOs of biosimilar companies must invest sufficient time in understanding the analytical characterization program to govern its development intelligently. Analytical similarity is not a binary pass/fail assessment: it involves a totality-of-evidence evaluation across a large number of quality attributes, and the FDA’s expectation for the depth and rigor of this characterization has increased as the agency’s biosimilar review experience has grown.
The CEO’s time investment in the development phase should include: regular scientific reviews of the analytical characterization program with the CMC team, oversight of the comparability exercise design (which lots of reference product are used and from which markets), and governance of the decision about what clinical data package will accompany the submission. Some biosimilar programs have pursued approval with only PK/PD clinical data and no efficacy trial, relying on analytical similarity to bridge; others include confirmatory efficacy trials. This is a CEO-level strategic decision with significant cost and timeline implications.
FDA’s biosimilar product development guidance outlines the current framework for 351(k) applications and interchangeability determinations.
Interchangeability Designation: A Strategic Decision with Commercial Consequences
The interchangeability designation allows a biosimilar to be substituted for the reference product by a pharmacist without a physician intervention, in states that have enacted pharmacy substitution laws. The designation requires additional switching study data demonstrating that alternating patients between the reference product and the biosimilar does not produce diminished efficacy or increased safety risk.
For biosimilar CEOs, the decision to pursue interchangeability designation is not simply a regulatory strategy question. It is a commercial strategy question with capital allocation implications. The switching study required for interchangeability adds cost and time to the development program. The commercial benefit of interchangeability is real but variable depending on the therapeutic category: in a physician-administered biologic setting (oncology, hospital-based treatments), interchangeability matters less than in a self-injected outpatient setting where pharmacy-level substitution can drive formulary-preferred positioning.
The CEO must invest time in evaluating the interchangeability decision for each product in the portfolio with specificity about the commercial context. A single framework applied across all programs will likely produce the wrong answer for some programs and the right answer for others.
Payer and Formulary Relationship Management
Market access for biosimilars is determined primarily by payer formulary placement decisions: whether the payer places the biosimilar in the same tier as the reference product, grants it preferred formulary status, or requires step therapy through the biosimilar before authorizing the reference product. These decisions are made by pharmacy and therapeutics committees at large health plans and PBMs, and the biosimilar company CEO must invest time in the relationships with payer leadership that influence these decisions.
The commercial case for a biosimilar is, in theory, straightforward: equivalent clinical performance at lower cost. In practice, payer formulary decisions for biologics are complicated by contracted rebate arrangements, patient and physician preferences for established reference products, and the administrative costs of managing therapeutic switching for patients who are stable on the reference product.
The CEO’s payer engagement strategy should be built around two distinct activities: evidence generation to support formulary decisions, and direct payer relationship management. On evidence generation, the CEO governs the real-world evidence program, the cost-effectiveness modeling, and the budget impact analyses that the market access team presents to payers. On relationship management, the CEO maintains direct relationships with chief pharmacy officers and medical directors at the top 10 to 15 payers by covered lives, supplemented by engagement with PBM pharmaceutical management leadership.
For a biosimilar company launching into competitive markets, the first 90 days post-approval are the window during which formulary positioning is determined for the first coverage year. The CEO must ensure the market access team is ready to engage payers at the moment of approval with fully prepared dossiers, budget impact models, and pricing proposals. This readiness requires CEO-level governance of market access preparation, beginning 12 to 18 months before anticipated approval.
Competitive Launch Timing Against Reference Products
The biosimilar market for any given reference product is not occupied by a single biosimilar. Multiple biosimilar developers typically receive approval for the same molecule across an 18 to 36-month period after initial patent expiration. The competitive dynamics among biosimilar developers are determined by timing of entry, pricing strategy, and early formulary wins.
The first biosimilar to market for a given reference product has historically captured a disproportionate share of the biosimilar adoption curve, because payers tend to add the first available biosimilar to formulary and then require competitive bids from subsequent entrants for preferred positioning. The CEO of a biosimilar company must therefore invest significant time in the competitive intelligence and launch timing decision process.
Key questions the CEO must be prepared to answer with genuine command of the facts: What is the current patent litigation status for the reference product, including the 12-year exclusivity period under the BPCIA, any Orange Book-style patent challenges, and the patent dance status with the reference product manufacturer? What are the anticipated approval dates for competitive biosimilars targeting the same molecule? What is the company’s manufacturing readiness to supply at launch?
The launch timing decision may also be affected by authorized generic or authorized biosimilar strategies employed by the reference product manufacturer. Some innovator companies have negotiated early launch agreements with biosimilar developers to manage competition strategically. The CEO must have sufficient command of the competitive landscape to evaluate these strategies accurately.
For broader context on how pharma CEOs manage commercial launches, pharma CEO time management for a global commercial launch covers the governance framework applicable to biosimilar launch execution.
Managing Reference Product Manufacturer Legal Strategies
Reference product manufacturers have developed extensive legal strategies to delay biosimilar market entry, including broad patent portfolios with sequential expiration dates (the “patent thicket”), citizen petition filings with FDA, and litigation strategies designed to delay approval through injunctions or settlement negotiations.
The biosimilar CEO must invest time in managing the legal strategy in parallel with the regulatory and commercial development program. This means close oversight of patent counsel, active engagement in strategic decisions about which patents to challenge versus design around, and governance of the BPCIA “patent dance” process (the formal pre-litigation patent notification and exchange mechanism).
Legal strategy decisions in biosimilar development are CEO-level decisions because they affect the launch timeline and therefore the entire commercial case. A decision to settle patent litigation for a delayed entry date has different financial implications than a decision to litigate through trial. These decisions require the CEO’s personal engagement, not just counsel’s recommendation.
Manufacturing Readiness and Supply Chain Governance
Biosimilar manufacturing at commercial scale requires validated manufacturing processes, qualified manufacturing sites (either internal or CMO), and supply chain arrangements for raw materials and drug substance that support both clinical supply and commercial launch quantities.
The CEO must invest time in manufacturing readiness governance, particularly in the 12 to 24 months before anticipated approval. Key milestones include: process performance qualification completion, pre-approval inspection readiness, supply agreement execution with distribution partners, and launch inventory build. A biosimilar that receives FDA approval but cannot supply the market within 30 to 60 days loses the first-mover advantage that the entire development investment was designed to capture.
Investor Communication for Biosimilar Companies
Biosimilar company investors, whether public market investors or private equity and venture capital in private biosimilar companies, require education about the specific dynamics of biosimilar market penetration. The narrative that biosimilar adoption should be rapid because the cost savings benefit is obvious does not match the historical reality of US biosimilar uptake, which has been slower than European markets due to payer rebate structures, physician resistance to switching, and formulary inertia.
The CEO must invest time in developing investor communication that accurately characterizes the biosimilar market access timeline, the expected formulary penetration curve, and the revenue ramp trajectory given these structural factors. Overpromising biosimilar adoption speed is one of the most common credibility errors in biosimilar CEO investor communications.
Conclusion: Biosimilar Company CEO Time Management as Execution Discipline
Biosimilar company CEO time management across development and market access is fundamentally a discipline of execution under time pressure. The development program, the regulatory strategy, the interchangeability decision, the payer engagement preparation, and the competitive launch timing decision are all interconnected, and slippage in any one area compounds across the others.
CEOs who maintain personal command of each dimension, investing protected time in the scientific, regulatory, commercial, and legal activities that determine the biosimilar’s market outcome, build companies that execute launches effectively. The biosimilar CEO who achieves early formulary preferred positioning, launches on schedule, and manages the competitive response has delivered the full value of the development investment. That outcome requires sustained, structured time management across every phase.
Related Reading
For further context, explore How Biopharma CEOs Manage Time During Merger and Acquisition Due Diligence and How Biotech CEOs Manage Time During IPO Readiness.